<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261831</url>
  </required_header>
  <id_info>
    <org_study_id>13 6936 03</org_study_id>
    <nct_id>NCT02261831</nct_id>
  </id_info>
  <brief_title>Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood</brief_title>
  <acronym>MICIMAB</acronym>
  <official_title>Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will compare 16sRDNA profile in cases and controls in order to identify
      bacteria associated with metabolic diseases that reside both in intestinal crypts and in
      blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental evidence suggests that bacterial translocation from gut to tissue could be an
      initial step leading to diabetes. To test this hypothesis, a bacterial component that is
      highly conserved between different species of bacteria, the 16S rDNA gene will be analysed
      both in intestinal crypt and in blood in patients with type 2 diabetes, obese patients and
      control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rDNA comparison between cases and controls</measure>
    <time_frame>36 months</time_frame>
    <description>Comparison of 16sRDNA profile in cases and controls in order to identify bacteria associated with metabolic diseases that reside both in intestinal crypts and in blood.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>obese patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients free of obesity and diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients free type 2 diabetes.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>obese patients</intervention_name>
    <description>collection of blood sampling and biopsies</description>
    <arm_group_label>obese patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diabetic patients</intervention_name>
    <description>collection of blood sampling and biopsies</description>
    <arm_group_label>Diabetic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patients free of obesity and diabetes</intervention_name>
    <description>collection of blood sampling and biopsies</description>
    <arm_group_label>Patients free of obesity and diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patients free type 2 diabetes</intervention_name>
    <description>collection of blood sampling and biopsies</description>
    <arm_group_label>patients free type 2 diabetes.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 35 and 75 years old

          -  Colonoscopy and biopsies required

        Diabetes population:

          -  Type 2 diabetes

        Obese population:

          -  Android obesity

        Exclusion Criteria:

          -  Inflammatory bowel disease

          -  Colonic cancer

          -  Bariatric surgery

          -  Previous administration of antibiotic (within 15 days)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques AMAR, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Moreau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques Amar, MD PhD</last_name>
    <email>amar.j@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31 052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Pr Amar</last_name>
      <phone>05 61 32 30 15</phone>
      <phone_ext>+33</phone_ext>
      <email>amar.j@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jacques Pr Moreau</last_name>
      <phone>05 61 32 30 15</phone>
      <phone_ext>+33</phone_ext>
      <email>moreau.j@chu-toulouse.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bacterial</keyword>
  <keyword>gut</keyword>
  <keyword>type 2 diabetes.</keyword>
  <keyword>16S rDNA gene</keyword>
  <keyword>intestinal crypt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

